Haemonetics Co. Logo
US4050241003
881782
HAE

Haemonetics Co.

Loading quotes...

Forecast

The analysts' average price target is €116.88 (+9.23%). The median is €116.16 (+8.56%).

Buy
  12
Hold
  9
Sell
  0

Financials

In the last quarter, Haemonetics Co. had revenue of €297.88M and net profit of €28.97M
(EUR) June 2026
YoY
Revenue 297.88M 8.62%
Gross profit 178M 8.73%
Net profit 28.97M 0.23%
EBITDA 65.55M 18.01%

Fundamentals

Metric Value
Market capitalization
€4.86B
Number of shares
45.5M
52-week high/low
€110.59 - €43.78
Dividends No
Beta
0.54
P/E ratio
58.08
PEG ratio
-1.55
P/B ratio
6.48
P/S ratio
4.03

Company profile

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Name
Haemonetics Co.
CEO
Christopher A. Simon
Headquarters Boston, ma
USA
Website
Sector
Consumer Discretionary
Industry
Household Durables
IPO
05/10/1991
Employees 3,009

Ticker symbols

Exchange Symbol
NYSE
HAE
Frankfurt
HAZ.F
DĂĽsseldorf
HAZ.DU
MĂĽnchen
HAZ.MU
🍪

Parqet  uses cookies. Learn more